Month: December 2020

– Company invests to build in-house capabilities to support advancement of pipeline –– In combination with dedicated CGMP suite at Catalent, the new laboratory creates foundation for integrated AAV gene therapy manufacturing –PHILADELPHIA, Dec. 16, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced that it has entered into a long-term lease to support Chemistry, Manufacturing and Controls (CMC) laboratory operations for the company’s gene therapy programs. The new laboratory, slated to open in the second quarter of 2021 at the Princeton West Innovation Campus in Hopewell, New Jersey, will initially focus on state-of-the-art analytical capabilities, clinical...

ROSELAND, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today reported that the Company’s Interim CEO, Leonard Osser, plans to exercise up to 336,970 options. In connection with the transaction, he plans to sell a portion of his shares to cover the cost of the options and associated taxes. However, the net impact of the transaction will be an increase in Mr. Osser’s overall common stock holdings. Mr. Osser has no plans to sell additional shares.About Milestone Scientific Inc.Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments...

JACKSONVILLE, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) — Regency Centers Corporation (The “Company”) (NASDAQ: REG) will announce its Fourth Quarter 2020 earnings results on Thursday, February 11, 2021, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Friday, February 12, 2021, at 12:00 p.m. ET.ReplayWebcast Archive: Investor Relations page under Webcasts & PresentationsAbout Regency Centers Corporation (NASDAQ: REG)Regency Centers is the preeminent national owner, operator, and developer of shopping centers located in affluent and densely populated trade areas. Operating as a fully integrated real estate company, Regency Centers...

QUEBEC CITY, Dec. 16, 2020 (GLOBE NEWSWIRE) — (TSXV: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is proud to announce its business line Piedmont, a global leader in corrosion resistant equipment for desalination plants in the industrial and municipal markets, secured three large orders for fiber reinforced polyester (“FRP”) cartridge filter housings and duplex stainless couplings, totalling $3.3 M. The team also signed two new distribution agreements in new geographies.Over the last few months, Piedmont has received several new contracts for the supply of FRP cartridge filter housings, cartridge filtration elements as well as flexible couplings of small to medium sizes. Today, the contracted scope is for three new large-scale seawater reverse osmosis (“RO”) desalination plants. Two of these desalination plants...

QUÉBEC, 16 déc. 2020 (GLOBE NEWSWIRE) — (TSXV : HEO) – H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière d’annoncer aujourd’hui que sa ligne d’affaires Piedmont, leader mondial dans l’équipement anticorrosif pour les usines de dessalement d’eau de mer pour les marchés industriels et municipaux, a remporté trois importants contrats de filtres à cartouches renforcés de fibres de verre (« FRP ») et de raccords duplex en acier inoxydable, totalisant 3,3 M $. L’équipe a également signé deux nouveaux accords de distribution dans de nouvelles zones géographiques.Au cours des derniers mois, Piedmont a reçu plusieurs nouveaux contrats pour la fourniture de filtres à cartouches faits de FRP, d’éléments de filtres à cartouches ainsi que de raccords flexibles de petites et de moyennes tailles. Aujourd’hui,...

COMPANY ANNOUNCEMENTNo. 71/2020Tvis, 16 December 2020Financial calendar 2021The Board of Directors of TCM Group A/S has set the following dates for publication of the interim reports, annual reports and annual general meeting:24 February 2021                               Interim report Q4 2020 and Annual report 20202 March 2021                                     Deadline for submission of shareholder proposals to Annual General Meeting13 April 2021                                      Annual General Meeting19 May 2021                                      Interim report Q1 202120 August 2021                                  Interim report Q2 202112 November 2021                             Interim report Q3 202125 February 2022                               Interim report Q4 2021 and Annual report 20215 April 2022                   ...

SELSKABSMEDDELELSENr. 71/2020Tvis, 16. december 2020Finanskalender 2021Finanskalenderen indeholder de forventede datoer for offentliggørelse af delårsrapporter, årsrapporter og afholdelse af generalforsamling:24. februar 2021                                                         Delårsrapport for 4. kvartal 2020 og årsrapport for 20202. marts 2021                                                             Frist for indsendelse af aktionærforslag til generalforsamling13. april 2021                                                             Ordinær generalforsamling19. maj 2021                                                              Delårsrapport for 1. kvartal 202120. august 2021                                                          Delårsrapport for 2. kvartal 202112. november 2021                                         ...

Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities.Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 3,700 people with early Alzheimer’s disease. The programme is planned for initiation in the first half of 2021 and will investigate the efficacy and safety of once-daily oral semaglutide, compared to placebo. The expected main treatment period in the trials is around two years.“As a company we aspire to address...